These innovative molecules represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose https://carlyxzgp498585.blogs100.com/39584828/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide